# Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

> **NCT05156970** · PHASE2 · COMPLETED · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 81 (actual)

## Conditions studied

- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Apatinib Mesylate
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05156970
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-24
- **Primary completion:** 2024-06-24
- **Final completion:** 2025-06-24
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156970, "Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05156970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*